NEW YORK and HAIKOU CITY, China, Nov. 5 /Xinhua-PRNewswire-FirstCall/ -- China Pharma Holdings, Inc. ("China Pharma") (OTC Bulletin Board: CPHI) which develops, manufactures, and markets generic and branded bio-pharmaceutical products in China, today announced it will release its third Quarter 2008 results on Friday, November 7, 2008. In conjunction, the Company will host an earning conference call at 10:00 a.m. EST on Friday, November 7, 2008 to discuss these results.
Ms. Zhilin Li, President and CEO of China Pharma Holdings, Inc., Mr. Xinhua Wu, Chief Financial Officer, and Ms. Sara Ephraim, Vice President of the company's IR firm, The Ruth Group, will be hosting the call. To participate in the conference call, please dial 1-800-591-6945 ten minutes prior to the scheduled conference call time. International callers should dial 1-617-614-4911. The conference pass code is 57906502.
If you are unable to participate in the call at this time, a replay will be available on Friday, November 7 at 12:00 p.m. EST, through Friday, November 14. To access the replay, please dial 1-888-286-8010. International callers should dial 1-617-801-6888. The conference pass code is 19590263. This conference call will be broadcast live over the Internet and can be accessed by clicking this link: http://phx.corporate-ir.net/playerlink.zhtml?c=145098&s=wm&e=2018680 . A replay will also be available shortly after the call on China Pharma' website http://www.chinapharmaholdings.com .
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. is a biopharmaceutical company with rapidly growing profit that develops, manufactures, and markets treatments for a wide range of high incidence and high mortality conditions in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective, high margin business model is driven by market demand and supported by 8 scalable GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding distribution network across 30 provinces, municipalities and autonomous regions. The Company is registered in Delaware, USA. Hainan Helpson Bio-pharmaceutical Co., Ltd (Helpson), located in Haikou City, Hainan Province, China, is a wholly owned subsidiary of China Pharma Holdings, Inc. For more information about China Pharma Holdings, Inc., please visit http://www.chinapharmaholdings.com .
Safe Harbor Statement: Certain statements in this press release and
oral statements made by China Pharma on its conference call in relation to
this release, constitute forward-looking statements for purposes of the
safe harbor provisions under The Private Securities Litigation Reform Act
of 1995. Any statements set forth above that are not historical facts are
forward-looking statements that involve risks and uncertainties that could
cause actual results to differ materially from those in the forward-looking
statements, which may include, but are not limited to, such factors as
unanticipated changes in product demand, increased competition, failure to
obtain or maintain intellectual property protection, downturns in the
Chinese economy, uncompetitive levels of research and development, failure
to obtain regulatory approvals, and other information detailed from time to
time in the Company's filings and future filings with the United States
Securities and Exchange Commission. The forward-looking statements made
herein speak only as of the date of this press release and the Company
undertakes no duty to update any forward-looking statement to conform the
statement to actual results or changes in the company's expectations.
For more information, please contact:
China Pharma Holdings, Inc.
The Ruth Group
|SOURCE China Pharma Holdings, Inc.|
Copyright©2008 PR Newswire.
All rights reserved